In this episode, we explore the latest advances in treating estrogen receptor-positive (ER+) breast cancer, with a spotlight on lasofoxifene, a next-generation hormonal therapy showing promise for patients with advanced disease and bone metastasis.You’ll learn:Why is such a common site for ER+ breast cancer metastasisHow traditional endocrine therapies can weaken bone health and impact quality of lifeThe unique dual action of lasofoxifene in both breast and bone tissueKey insights from the ELAINE-1, ELAINE-2, and ELAINE-3 clinical trialsHow lasofoxifene could reshape treatment for ESR1-mutated breast cancersPotential benefits beyond tumor control, including bone protection and fewer side effectsThe role of combination therapies with CDK4/6 and PI3K inhibitors in improving outcomesHow future research in immune competence and precision oncology may refine treatment strategiesWith its ability to suppress tumor growth while preserving bone density, lasofoxifene represents a promising shift in ER+ breast cancer therapy, one that prioritizes both survival and quality of life.Blog Link: New Advances in ER+ Breast Cancer TherapySend us a textThank you for listening to The Onco Life Podcast, your trusted source for expert cancer information and patient-centered education. Author: Dr. CHRISTINA NG VAN TZE 📍 Visit us at oncolifecentre.com 📞 Call: +603-2242-2620 📧 Book a consultation or ask a question — we're here to support your journey.

Ver todos los episodios